Kura Oncology Q1 2026: $5.8M KOMZIFTI net revenue in first full commercial quarter; cash $580.8M

Kura Oncology, Inc.

2026-Q1 EPS reported -$0.83 vs consensus -$0.65 ▼ miss (-28.6%)

Net product revenue $5.8M from KOMZIFTI in first full commercial quarter; 85 new patient starts, 157 total prescriptions.
Net loss $73.3M (Q1 2025: $57.4M); R&D expense $65.3M, SG&A $31.6M on commercialization investments.
Cash $580.8M plus $180M anticipated Kyowa Kirin payments expected to fund ziftomenib program through 2028.
Payer coverage >93% across >12M lives; early adoption includes repeat use, switching from other menin inhibitors.
Multiple 2026 catalysts: EHA updated KOMET-007 data, ASCO darlifarnib/adagrasib data, KOMET-008 preliminary data.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Kura Oncology, Inc. reported first quarter ended March 31, 2026 results: revenue $5.8 million.

Period: first quarter ended March 31, 2026
Revenue: $5.8 million
Result: reported results

Exact text from the filing

identified as being incorporated therein by reference. --- EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Kura Oncology Reports FIRST Quarter 2026 Financial Results – $5.8 million in KOMZIFTITM (ziftomenib) net product revenue in first full quarter of commercialization – – Robust new patient starts and early launch dynamics, including repeat use, switching

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-219422

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.